Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

CSL Behring (Australia) Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (198)
Cancellation by sponsor (15)
Australian Public Assessment Report (AusPAR) (3)
Prescription medicine decision summary (1)
Prescription medicine evaluation (1)

Date

2026 (5)
2025 (17)
2024 (13)
2023 (9)
2022 (10)
2021 (1)
2020 (22)
2019 (1)
2018 (3)
2017 (13)
2016 (6)
2015 (7)
2014 (5)
2013 (4)
2012 (5)
2011 (6)
2010 (11)
2009 (9)
2008 (4)
2007 (1)
2006 (25)
2005 (3)
2001 (1)
2000 (6)
1999 (5)
1998 (12)
1997 (3)
1995 (7)
1994 (1)
1991 (3)

Search

Sponsor content

218 result(s) found, displaying 11 to 20

CSL United States of America Privigen normal immunoglobulin (human) 10g (100g/L, 10%) solution for intravenous solution Cancelled under Section 30(1)(c) of the Act

2 September 2025

Cancellation by sponsor

Requested by CSL Behring (Australia) Pty Ltd
HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 50 mL pre-filled syringe (457854)

17 February 2025

ARTG

Australian Register of Therapeutic Goods (ARTG) information for HIZENTRA human normal immunoglobulin 20% solution for subcutaneous injection 50 mL pre-filled syringe.
ANDEMBRY garadacimab 200 mg solution for injection in pre-filled pen (443611)

14 January 2025

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ANDEMBRY garadacimab 200 mg solution for injection in pre-filled pen.
ANDEMBRY garadacimab 200 mg solution for injection in pre-filled syringe with needle safety device (428253)

14 January 2025

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ANDEMBRY garadacimab 200 mg solution for injection in pre-filled syringe with needle safety device.
CSL US AlbuRx 5 human albumin 50 g/L (5% w/v) solution for intravenous infusion vial (470325)

25 November 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for CSL US AlbuRx 5 human albumin 50 g/L (5% w/v) solution for intravenous infusion vial.
CSL New Zealand EVOGAM Normal Immunoglobulin (human) 16% (3.2 g/20 mL), Injection Solution Vial for Subcutaneous Use Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by CSL Behring (Australia) Pty Ltd
CSL New Zealand EVOGAM Normal Immunoglobulin (human) 16% (1.6 g/10 mL), Injection Solution Vial for Subcutaneous Use Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by CSL Behring (Australia) Pty Ltd
CSL New Zealand EVOGAM Normal Immunoglobulin (human) 16% (0.8 g/5 mL), Injection Solution Vial for Subcutaneous Use Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by CSL Behring (Australia) Pty Ltd
EVOGAM normal immunoglobulin (human) 16% w/v, 3.2g/20mL injection solution vial for subcutaneous use Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by CSL Behring (Australia) Pty Ltd
EVOGAM normal immunoglobulin (human) 16% w/v, 1.6g/10mL injection solution vial for subcutaneous use Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by CSL Behring (Australia) Pty Ltd

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.